PRIMARY ANALYSIS RESULTS OF THE SINGLE‐ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (L‐MIND) | Publicación